(Q35043933)

6 August 2017

2 references

6 November 2020

17 February 2023

TP53 status and response to treatment in breast cancers (English)

1 reference

6 August 2017

2 references

6 November 2020

17 February 2023

1 reference

6 November 2020

1 reference

author

Louis-François Plassa

series ordinal

3

object named as

Louis-François Plassa

1 reference

6 August 2017

4

Philippe Bertheau

1 reference

6 August 2017

5

Anne Janin

1 reference

6 August 2017

1

Mariana Varna

1 reference

6 August 2017

2

Guilhem Bousquet

1 reference

6 August 2017

publication date

9 May 2011

9 references

Journal of Biomedicine and Biotechnology

6 August 2017

13 March 2019

3 April 2019

20 June 2019

17 June 2019

30 June 2019

14 September 2019

6 November 2020

17 February 2023

9 references

6 August 2017

13 March 2019

3 April 2019

20 June 2019

17 June 2019

30 June 2019

14 September 2019

6 November 2020

17 February 2023

2011

1 reference

6 August 2017

page(s)

284584

1 reference

Creative Commons Attribution 3.0 Unported

6 August 2017

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53 and autophagy in cancer: guardian of the genome meets guardian of the proteome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Autophagy regulation by p53.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Triple-negative breast cancer--current status and future directions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

A common gain of function of p53 cancer mutants in inducing genetic instability

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

TP53 status and response to chemotherapy in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Regulation of autophagy by cytoplasmic p53

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Death through a tragedy: mitotic catastrophe

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Two faces of p53: aging and tumor suppression

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Shaping genetic alterations in human cancer: the p53 mutation paradigm

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Changes in allelic imbalances in locally advanced breast cancers after chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Histone deacetylase inhibitors: signalling towards p21cip1/waf1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53 alterations in human cancer: more questions than answers.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53 modulation of the DNA damage response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Molecular classification of breast cancer: limitations and potential

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

DRAM, a p53-induced modulator of autophagy, is critical for apoptosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53 and breast cancer, an update

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

The p53 pathway: positive and negative feedback loops

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

The signals and pathways activating cellular senescence

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Cell death by mitotic catastrophe: a molecular definition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

To die or not to die: how does p53 decide?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p73 and p63 protein stability: the way to regulate function?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

When p53 needs p73 to be functional - forced p73 expression induces nuclear accumulation of endogenous p53 protein

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53 has a direct apoptogenic role at the mitochondria

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Genetic Stabilization by p53 Involves Growth Regulatory and Repair Pathways

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Revision of the American Joint Committee on Cancer staging system for breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

The evolution of diverse biological responses to DNA damage: insights from yeast and p53.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

C-terminal ubiquitination of p53 contributes to nuclear export

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Activation of the HIF pathway in cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

8 July 2018

Surfing the p53 network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Molecular portraits of human breast tumours

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

The p53 tumor suppressor gene: from molecular biology to clinical investigation.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

A simple p53 functional assay for screening cell lines, blood, and tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Mutation and Expression of TP53 in Malignant Melanomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Structural aspects of the p53 protein in relation to gene evolution

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

8 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

The C terminus of p53 binds the N-terminal domain of MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Mutant p53 protein localized in the cytoplasm inhibits autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Mdm2 plays a positive role as an effector of p53-dependent responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

p53 as a specific prognostic factor in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

25 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F284584

Neoangiogenesis in colon cancer: correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114547

p53 status and the efficacy of cancer therapy in vivo

9 December 2018

1 reference

12 December 2020

Breast cancer: epidemiology and risk factors

1 reference

12 December 2020

Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer

1 reference

12 December 2020

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

1 reference

12 December 2020

A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients

1 reference

12 December 2020

Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy

1 reference

12 December 2020

High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer

1 reference

12 December 2020

Types and localisation of p53 gene mutations: a report on 332 non-small cell lung cancer patients

1 reference

12 December 2020

Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection

1 reference

12 December 2020

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support

1 reference

12 December 2020

P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach

1 reference

12 December 2020

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

12 December 2020

p53, vessel count, and vascular endothelial growth factor expression in human colon cancer

1 reference

12 December 2020

The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/284584

1 reference

release_do6uqd4mknecfb4rk6ocmus6he

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/do6uqd4mknecfb4rk6ocmus6he

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3114547

1 reference

6 August 2017

1 reference